CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
CHINA PHARMA HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.69−0.02 (-3.49%)
Close on Oct 19, 2026
- Market cap
- $27.76M
- P/E (TTM)
- –
- Dividend yield
- –
China Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | China Pharma | Industry median |
|---|---|---|
| Market Cap | $29.47M | $197.05M |
| Enterprise Value | $30.81M | $106.56M |
| PS Ratio | 7.53 | 3.93 |
| PB Ratio | 0.81 | 2.14 |
Enterprise value
| Measure | China Pharma | Industry median |
|---|---|---|
| EV / Sales | 7.87 | 2.69 |
Income (trailing twelve months)
| Measure | China Pharma | Industry median |
|---|---|---|
| Revenue | $3.91M | $57.94M |
| Gross Profit | $460.17K | $90.47M |
| Operating Income | -$4.38M | -$21.44M |
| Pretax Income | -$4.47M | -$14.45M |
| Net Income | -$4.47M | -$22.46M |
| EBITDA | -$1.44M | -$16.91M |
| EPS (Diluted) | -$0.43 | -$0.83 |
Margins
| Measure | China Pharma | Industry median |
|---|---|---|
| Gross Margin | 11.8% | 52.3% |
| Operating Margin | -111.8% | -44.5% |
| Pretax Margin | -114.3% | -13.0% |
| Profit Margin | -114.3% | -39.2% |
| EBITDA Margin | -36.8% | -31.3% |
Returns
| Measure | China Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -21.0% | -53.1% |
| Return on Assets (ROA) | -15.3% | -41.0% |
| Return on Invested Capital (ROIC) | -15.5% | -32.0% |
| Return on Capital Employed (ROCE) | -11.8% | -37.8% |
Growth
| Measure | China Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -11.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -20.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -17.5% | 6.42% |
Balance sheet
| Measure | China Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $304.87K | $62.42M |
| Total Debt | $1.64M | $120.13M |
| Net Cash (Debt) | -$1.34M | $15.68M |
| Net Cash Per Share | -$0.03 | $0.65 |
| Equity (Book Value) | $36.18M | $48.79M |
| Book Value Per Share | $0.84 | $1.36 |
| Tangible Book Value | -$2.16M | $23.06M |
| Working Capital | -$5.67M | $75.77M |
Financial position
| Measure | China Pharma | Industry median |
|---|---|---|
| Current Ratio | 0.26 | 3.30 |
| Quick Ratio | 0.06 | 2.39 |
| Debt / Equity | 0.05 | 0.51 |
| Interest Coverage | -136.50 | -7.12 |
Cash flow (trailing twelve months)
| Measure | China Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$140.49K | -$12.35M |
Efficiency
| Measure | China Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Inventory Turnover | 2.27 | 2.67 |
| Revenue Per Employee | $17.71K | $398.96K |
| Profits Per Employee | -$20.25K | -$732.08K |
| Employee Count | 221 | 73 |
Dividends and yields
| Measure | China Pharma | Industry median |
|---|---|---|
| Earnings Yield | -15.2% | -21.2% |
Shares
| Measure | China Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 43,022,000 | 59,128,900 |
| Shares Change (YoY) | 629.2% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 43,022,000 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
| Shares Held by Institutions | 0.47% | 59.4% |
Scores
| Measure | China Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 0.13 | 0.10 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from China Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.